Johan Hansson
Overview
Explore the profile of Johan Hansson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
198
Citations
8456
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brodin D, Tornhammar P, Ueda P, Krifors A, Westerlund E, Athlin S, et al.
BMJ Open
. 2023 Feb;
13(2):e064374.
PMID: 36813503
Objective: To assess the efficacy of inhaled ciclesonide in reducing the duration of oxygen therapy (an indicator of time to clinical improvement) among adults hospitalised with COVID-19. Design: Multicentre, randomised,...
2.
Naeser Y, Helgadottir H, Hansson J, Ingvar C, Elander N, Flygare P, et al.
Cancers (Basel)
. 2022 Feb;
14(4).
PMID: 35205786
The benefit of imaging in the follow-up setting for high-risk melanoma patients is uncertain, and even less is known about the impact of intensive follow-up on the patient´s quality of...
3.
Falkenius J, Keskitalo J, Kanter L, Johansson H, Hoiom V, Hansson J, et al.
Acta Oncol
. 2021 Oct;
61(1):14-21.
PMID: 34694198
Background: Ulceration is an independent adverse prognostic factor in cutaneous malignant melanoma (CMM). There is, however, a need for additional prognostic markers to identify patients with ulcerated stage I-II CMM...
4.
Das I, Tuominen R, Helleday T, Hansson J, Berglund U, Egyhazi Brage S
J Invest Dermatol
. 2021 Aug;
142(3 Pt A):736-740.e6.
PMID: 34418425
No abstract available.
5.
Vidarsdottir L, Azimi A, Das I, Sigvaldadottir I, Suryo Rahmanto A, Petri A, et al.
Sci Rep
. 2021 May;
11(1):11023.
PMID: 34040017
BRAF inhibitors (BRAFi) selectively target oncogenic BRAF and are effective in 80% of advanced cutaneous malignant melanoma cases carrying the V600 mutation. However, the development of drug resistance limits their...
6.
Rad Pour S, Pico de Coana Y, Demorentin X, Melief J, Thimma M, Wolodarski M, et al.
J Immunother Cancer
. 2021 May;
9(5).
PMID: 33963011
Background: While programmed cell death receptor 1 (PD-1) blockade treatment has revolutionized treatment of patients with melanoma, clinical outcomes are highly variable, and only a fraction of patients show durable...
7.
Lacson J, Zamani S, Froes Jr L, Mitra N, Qian L, Doyle S, et al.
BMC Public Health
. 2021 Apr;
21(1):692.
PMID: 33888076
Background: Individuals from melanoma-prone families have similar or reduced sun-protective behaviors compared to the general population. Studies on trends in sun-related behaviors have been temporally and geographically limited. Methods: Individuals...
8.
Naeser Y, Helgadottir H, Brandberg Y, Hansson J, Olofsson Bagge R, Elander N, et al.
BMC Cancer
. 2020 Dec;
20(1):1197.
PMID: 33287744
Background: The incidence of cutaneous malignant melanoma (CMM) is increasing worldwide. In Sweden, over 4600 cases were diagnosed in 2018. The prognosis after radical surgery varies considerably with tumor stage....
9.
Das I, Chen H, Maddalo G, Tuominen R, Rebecca V, Herlyn M, et al.
Cell Death Dis
. 2020 Oct;
11(10):882.
PMID: 33082316
Current treatment modalities for disseminated cutaneous malignant melanoma (CMM) improve survival, however disease progression commonly ensues. In a previous study we identified afatinib and crizotinib in combination as a novel...
10.
Eriksson H, Hansson J, Krynitz B, Masucci G, Girnita A, Lapins J, et al.
Acta Derm Venereol
. 2020 Sep;
100(18):adv00334.
PMID: 32985676
No abstract available.